<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>Pathophilia</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/" />
    <link rel="self" type="application/atom+xml" href="http://bmartinmd.com/atom.xml" />
    <id>tag:bmartinmd.com,2007-10-12://1</id>
    <updated>2012-05-16T14:45:32Z</updated>
    <subtitle>For the love of disease.</subtitle>
    <generator uri="http://www.sixapart.com/movabletype/">Movable Type Publishing Platform 4.01</generator>

<entry>
    <title>Novel Anti-Amyloid MAb to Be Studied in Familial Alzheimer&apos;s</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/05/novel-antiamyloid-mab-pre-ad.html" />
    <id>tag:bmartinmd.com,2012://1.1215</id>

    <published>2012-05-16T13:53:45Z</published>
    <updated>2012-05-16T14:45:32Z</updated>

    <summary>A remarkable, unprecedented development. Roche&apos;s anti-amyloid MAb, crenezumab (for which there are no entries at PubMed—!), will be given in an attempt to stave off familial Alzheimer disease. According to Reuters and the NYT, the experimental drug will be studied...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        A remarkable, unprecedented development. Roche&apos;s anti-amyloid MAb, crenezumab (for which there are no entries at PubMed—!), will be given in an attempt to stave off familial Alzheimer disease. According to Reuters and the NYT, the experimental drug will be studied...
        
    </content>
</entry>

<entry>
    <title>FDA Extends Cardiovascular Monitoring for Gilenya</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/05/fda-extends-gilenya-monitoring.html" />
    <id>tag:bmartinmd.com,2012://1.1214</id>

    <published>2012-05-15T12:52:01Z</published>
    <updated>2012-05-15T13:25:07Z</updated>

    <summary>The FDA has revised its recommendations for cardiovascular monitoring after the initiation of Gilenya (fingolimod), Novartis&apos;s oral drug for relapsing-remitting MS. The new recommendations, which extend the post-dosage monitoring for bradycardia from 6 to 24 hours, are based on the...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Cardiology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="FDA" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="multiplesclerosis" label="multiple sclerosis" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        The FDA has revised its recommendations for cardiovascular monitoring after the initiation of Gilenya (fingolimod), Novartis&apos;s oral drug for relapsing-remitting MS. The new recommendations, which extend the post-dosage monitoring for bradycardia from 6 to 24 hours, are based on the...
        
    </content>
</entry>

<entry>
    <title>FDA Warns of Risks With &quot;Liberation Procedure&quot;</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/05/fda-warns-of-risks-with-liberation-procedure.html" />
    <id>tag:bmartinmd.com,2012://1.1212</id>

    <published>2012-05-10T14:58:26Z</published>
    <updated>2012-05-10T15:17:00Z</updated>

    <summary>This morning, the FDA has finally stepped in and is warning healthcare professionals and MS patients alike about death and other injuries associated with the so-called &quot;liberation procedure&quot; (ugh), which amounts to either angioplasty or stenting of (typically) jugular veins....</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Ethics" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="FDA" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="multiplesclerosis" label="multiple sclerosis" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        This morning, the FDA has finally stepped in and is warning healthcare professionals and MS patients alike about death and other injuries associated with the so-called &quot;liberation procedure&quot; (ugh), which amounts to either angioplasty or stenting of (typically) jugular veins....
        
    </content>
</entry>

<entry>
    <title>Results of Phase 3 MAb Trials in Alzheimer Disease Are Hotly Anticipated</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/05/phase-3-mab-trials-in-ad.html" />
    <id>tag:bmartinmd.com,2012://1.1210</id>

    <published>2012-05-03T15:14:45Z</published>
    <updated>2012-05-03T15:48:12Z</updated>

    <summary>For the Internet&apos;s edification, the phase 3 trials of MAbs in AD are tabulated by drug (bapineuzumab, solanezumab) and expected completion date. Although the phase 3 trial of bapineuzumab in APOE Normal 0 false false false EN-US X-NONE X-NONE /*...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        For the Internet&apos;s edification, the phase 3 trials of MAbs in AD are tabulated by drug (bapineuzumab, solanezumab) and expected completion date. Although the phase 3 trial of bapineuzumab in APOE Normal 0 false false false EN-US X-NONE X-NONE /*...
        
    </content>
</entry>

<entry>
    <title>Venous Insufficiency in MS: Two More Studies Fail to Replicate Zamboni Data</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/05/studies-fail-to-replicate-zamboni.html" />
    <id>tag:bmartinmd.com,2012://1.1209</id>

    <published>2012-05-02T14:10:24Z</published>
    <updated>2012-05-02T15:05:09Z</updated>

    <summary>Chronic cerebrospinal venous insufficiency (CCSVI) is neither common, nor more common, in patients with multiple sclerosis, say investigators at the University of Texas Health Sciences Center in Houston. According to 2 preliminary reports presented at the recent annual meeting of...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="multiplesclerosis" label="multiple sclerosis" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        Chronic cerebrospinal venous insufficiency (CCSVI) is neither common, nor more common, in patients with multiple sclerosis, say investigators at the University of Texas Health Sciences Center in Houston. According to 2 preliminary reports presented at the recent annual meeting of...
        
    </content>
</entry>

<entry>
    <title>Kick-Back Friday: #198</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/kickback-friday-198.html" />
    <id>tag:bmartinmd.com,2012://1.1207</id>

    <published>2012-04-27T22:59:50Z</published>
    <updated>2012-04-27T23:28:31Z</updated>

    <summary>Small Town Murder Songs (2010): A heavy and heavily mustachioed Peter Stormare (the kidnapping guy from Fargo) plays Walter, a born-again cop who investigates the local murder of a stripper in his rural Canadian town. However, director Ed Gass-Donnelly places...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Kick-Back Friday" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="kickbackfriday" label="Kick-Back Friday" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="movies" label="movies" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        Small Town Murder Songs (2010): A heavy and heavily mustachioed Peter Stormare (the kidnapping guy from Fargo) plays Walter, a born-again cop who investigates the local murder of a stripper in his rural Canadian town. However, director Ed Gass-Donnelly places...
        
    </content>
</entry>

<entry>
    <title>Many Physicians Regret Career Choice</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/physicians-regret-career-choice.html" />
    <id>tag:bmartinmd.com,2012://1.1206</id>

    <published>2012-04-27T13:03:13Z</published>
    <updated>2012-04-27T13:25:31Z</updated>

    <summary><![CDATA[According to Medscape's newly published (2012) report on physician income, almost half (46%) of the surveyed physicians (N &gt; 25,000) would not choose medicine as a career, and nearly 80% would not choose the same practice setting, if they had...]]></summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Health care" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Media" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Medical education" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="medicaleducation" label="medical education" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        <![CDATA[According to Medscape's newly published (2012) report on physician income, almost half (46%) of the surveyed physicians (N &gt; 25,000) would not choose medicine as a career, and nearly 80% would not choose the same practice setting, if they had...]]>
        
    </content>
</entry>

<entry>
    <title>Predicting the Supremes&apos; Decision on the Affordable Care Act</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/predicting-supremes-votes-aca.html" />
    <id>tag:bmartinmd.com,2012://1.1204</id>

    <published>2012-04-19T14:51:20Z</published>
    <updated>2012-04-19T15:47:40Z</updated>

    <summary>Law professor Mark Hall (Wake Forest) makes predictions in the latest NEJM about the Supreme Court&apos;s decision on the recently argued Affordable Care Act (ACA)—specifically with respect to the constitutionality of the individual insurance mandate. (Although frankly, anyone who&apos;s been...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Health care" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Legal" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Legislation" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="healthcarereform" label="healthcare reform" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="ppaca" label="PPACA" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        Law professor Mark Hall (Wake Forest) makes predictions in the latest NEJM about the Supreme Court&apos;s decision on the recently argued Affordable Care Act (ACA)—specifically with respect to the constitutionality of the individual insurance mandate. (Although frankly, anyone who&apos;s been...
        
    </content>
</entry>

<entry>
    <title>A Non-Rhetorical Question: What&apos;s the Accuracy of a Clinical Diagnosis of Alzheimer Disease?</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/accuracy-clinical-diagnosis-alzheimer.html" />
    <id>tag:bmartinmd.com,2012://1.1202</id>

    <published>2012-04-10T13:56:04Z</published>
    <updated>2012-04-11T03:16:43Z</updated>

    <summary>The use of Avid/Lilly&apos;s newly approved amyloid tracer, Amyvid, hinges on the accuracy (or inaccuracy) of a clinical diagnosis of Alzheimer disease (AD) during life. If the historic accuracy of a clinical diagnosis of AD is generally high—meaning the correlation...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="amyloid" label="amyloid" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        The use of Avid/Lilly&apos;s newly approved amyloid tracer, Amyvid, hinges on the accuracy (or inaccuracy) of a clinical diagnosis of Alzheimer disease (AD) during life. If the historic accuracy of a clinical diagnosis of AD is generally high—meaning the correlation...
        
    </content>
</entry>

<entry>
    <title>What if the FDA Approved an Imaging Agent, and Nobody Used It?</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/fda-approves-amyvid.html" />
    <id>tag:bmartinmd.com,2012://1.1201</id>

    <published>2012-04-09T14:49:04Z</published>
    <updated>2012-04-09T16:14:42Z</updated>

    <summary>Much to my disquiet, the FDA approved Amyvid (florbetapir), an amyloid imaging agent, late last Friday. The radiolabeled tag for amyloid-beta, which is intended to be used with PET scanning, latches onto the stuff of neuritic plaques in the brains...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="FDA" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="amyloid" label="amyloid" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        Much to my disquiet, the FDA approved Amyvid (florbetapir), an amyloid imaging agent, late last Friday. The radiolabeled tag for amyloid-beta, which is intended to be used with PET scanning, latches onto the stuff of neuritic plaques in the brains...
        
    </content>
</entry>

<entry>
    <title>WSJ Traces &quot;Murky Path&quot; of Fake Avastin</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/wsj-traces-murky-path-of-fake-avastin.html" />
    <id>tag:bmartinmd.com,2012://1.1200</id>

    <published>2012-04-05T14:43:14Z</published>
    <updated>2012-04-05T15:44:40Z</updated>

    <summary>And at least one questionable wholesaler, Thomas Houghton through his UK-based River East Supplies, appears to be involved in both the February and most recent transactions.The WSJ traces the route of fake Avastin that cropped up in the United States...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="FDA" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Legal" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Oncology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="avastin" label="Avastin" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="pharma" label="pharma" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        And at least one questionable wholesaler, Thomas Houghton through his UK-based River East Supplies, appears to be involved in both the February and most recent transactions.The WSJ traces the route of fake Avastin that cropped up in the United States...
        
    </content>
</entry>

<entry>
    <title>More Counterfeit Avastin (Altuzan) Pops Up in the US Market</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/more-counterfeit-avastin-pops-up.html" />
    <id>tag:bmartinmd.com,2012://1.1199</id>

    <published>2012-04-04T15:23:40Z</published>
    <updated>2012-04-04T16:02:49Z</updated>

    <summary>From the FDA. The facts (ma&apos;am):A counterfeit version of bevacizumab, disguised as Roche&apos;s Altuzan—a brand that is approved in Turkey but not the United States—was recently discovered.The product &quot;contained no active ingredient,&quot; although the agency didn&apos;t reveal what it did...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="FDA" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Legal" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Oncology" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="counterfeitdrugs" label="counterfeit drugs" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="fda" label="FDA" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        From the FDA. The facts (ma&apos;am):A counterfeit version of bevacizumab, disguised as Roche&apos;s Altuzan—a brand that is approved in Turkey but not the United States—was recently discovered.The product &quot;contained no active ingredient,&quot; although the agency didn&apos;t reveal what it did...
        
    </content>
</entry>

<entry>
    <title>Anti-Amyloid MAb May Affect Tau in Alzheimer Disease</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/antiamyloid-mab-may-affect-tau.html" />
    <id>tag:bmartinmd.com,2012://1.1198</id>

    <published>2012-04-03T13:17:12Z</published>
    <updated>2012-04-03T15:28:22Z</updated>

    <summary>With an emphasis on &quot;may.&quot; Newly published post-hoc data from bapineuzumab&apos;s phase 2 studies indicate that the anti-amyloid MAb reduces CSF levels of tau—a traditional downstream marker of neurodegeneration in AD (as well as in similar diseases). These data appear...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="amyloid" label="amyloid" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        With an emphasis on &quot;may.&quot; Newly published post-hoc data from bapineuzumab&apos;s phase 2 studies indicate that the anti-amyloid MAb reduces CSF levels of tau—a traditional downstream marker of neurodegeneration in AD (as well as in similar diseases). These data appear...
        
    </content>
</entry>

<entry>
    <title>WTF: The Runup on Elan Continues</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/04/runup-on-elan-continues.html" />
    <id>tag:bmartinmd.com,2012://1.1197</id>

    <published>2012-04-02T14:20:25Z</published>
    <updated>2012-04-02T15:12:41Z</updated>

    <summary>Presumably powered on expectations about bapineuzumab and its phase 3 results—which are expected to be released later this year (possibly at the AAIC in mid-July). But see Adam Fuerstein&apos;s article of March 19th for an appropriate, cautionary reminder.Bapineuzumab, an anti-amyloid...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Neurology" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Neuropsychiatry" scheme="http://www.sixapart.com/ns/types#category" />
    
        <category term="Pharma" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="alzheimersdisease" label="Alzheimer&apos;s disease" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="amyloid" label="amyloid" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        Presumably powered on expectations about bapineuzumab and its phase 3 results—which are expected to be released later this year (possibly at the AAIC in mid-July). But see Adam Fuerstein&apos;s article of March 19th for an appropriate, cautionary reminder.Bapineuzumab, an anti-amyloid...
        
    </content>
</entry>

<entry>
    <title>Kick-Back Friday: #197</title>
    <link rel="alternate" type="text/html" href="http://bmartinmd.com/2012/03/kickback-friday-197.html" />
    <id>tag:bmartinmd.com,2012://1.1196</id>

    <published>2012-03-31T01:24:49Z</published>
    <updated>2012-03-31T01:51:28Z</updated>

    <summary>The Guard (2011): John Michael McDonough, brother of Martin, directs the outstanding Irish character actor Brendan Gleeson in a wry, self-aware homage to the provincial Irish cop, or Garda. Gleeson is a highly unconventional officer who partners up with a...</summary>
    <author>
        <name>bmartin</name>
        <uri>http://www.pathophilia.com</uri>
    </author>
    
        <category term="Kick-Back Friday" scheme="http://www.sixapart.com/ns/types#category" />
    
    <category term="kickbackfriday" label="Kick-Back Friday" scheme="http://www.sixapart.com/ns/types#tag" />
    <category term="movie" label="movie" scheme="http://www.sixapart.com/ns/types#tag" />
    
    <content type="html" xml:lang="en" xml:base="http://bmartinmd.com/">
        The Guard (2011): John Michael McDonough, brother of Martin, directs the outstanding Irish character actor Brendan Gleeson in a wry, self-aware homage to the provincial Irish cop, or Garda. Gleeson is a highly unconventional officer who partners up with a...
        
    </content>
</entry>

</feed>


